cedazuridine: Clinical Trials

11 trials of cedazuridine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 3 terminated, 2 active not recruiting, 2 recruiting. 11 Phase 2, 7 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 211Completed 3, Terminated 3, Active not recruiting 2, Recruiting 2, Withdrawn 1
Phase 17Completed 3, Active not recruiting 2, Terminated 2
Phase 31Recruiting 1

Follow cedazuridine: new trials by email Literature Review of cedazuridine trials Research Report on cedazuridine

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients
Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET, Ivosidenib Oral Tablet, Hydroxyurea - Acute Myeloid Leukemia With Gene Mutations
Phase 2RecruitingPETHEMA Foundation502026-06-122026-11-17
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
KPT-8602, Inqovi, Bone marrow aspirate - Myelodysplastic Syndromes
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)32023-11-142025-12-02
PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes
IV Decitabine, Decitabine and cedazuridine, only Decitabine and cedazuridine - Myelodysplastic Syndromes
Phase 1 / Phase 2Active not recruitingOtsuka Beijing Research Institute722023-10-162026-10-16
Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant
Venetoclax, Decitabine, Cedazuridine - Recurrent Acute Myeloid Leukemia
Phase 2TerminatedSanjay Mohan12023-04-132026-01-09
BMS-986253 in Myelodysplastic Syndromes
Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253 - Myelodysplastic Syndromes
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)22022-11-292025-09-30
Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma
Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab - Malignant Melanoma
Phase 1 / Phase 2CompletedUniversity of Colorado, Denver82022-06-202026-11-09
A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes
Pevonedistat, Decitabine, Cedazuridine - Myelodysplastic Syndromes (MDS)
Phase 2WithdrawnTakeda2021-10-012021-09-29
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
Decitabine and Cedazuridine (ASTX727), Venetoclax - Acute Myeloid Leukemia
Phase 1 / Phase 2Active not recruitingTaiho Oncology, Inc.1012021-02-092026-10-06
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Azacitidine, ASTX030 (cedazuridine + azacitidine), Cedazuridine - Myelodysplastic Syndromes, Acute Myeloid Leukemia
Phase 2 / Phase 3RecruitingTaiho Oncology, Inc.3162020-05-212026-10-06
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
ASTX727 LD, ASTX727 SD - Myelodysplastic Syndromes
Phase 1 / Phase 2CompletedTaiho Oncology, Inc.1602018-07-272026-04-03
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
ASTX727 Dose Escalation, ASTX727 Dose Confirmation, ASTX727 Fixed-Dose Combination - Myelodysplastic Syndrome, MDS
Phase 1 / Phase 2CompletedAstex Pharmaceuticals, Inc.1302014-10-282024-08-27

Conditions studied

Myelodysplastic Syndromes (7)  ·  Leukemia, Myeloid, Acute (4)  ·  Anemia, Refractory, with Excess of Blasts (1)  ·  Cytopenia (1)  ·  Hematologic Diseases (1)  ·  Leukemia (1)  ·  Leukemia, Myelomonocytic, Chronic (1)  ·  Melanoma (1)

Sponsors

Taiho Oncology, Inc. (3)  ·  National Cancer Institute (NCI) (2)  ·  Astex Pharmaceuticals, Inc. (1)  ·  Otsuka Beijing Research Institute (1)  ·  PETHEMA Foundation (1)  ·  Sanjay Mohan (1)  ·  Takeda (1)  ·  University of Colorado, Denver (1)

Countries

United States (8)  ·  Canada (4)  ·  Spain (4)  ·  Germany (2)  ·  Italy (2)  ·  Belgium (1)  ·  China (1)  ·  Czechia (1)  ·  France (1)  ·  Hungary (1)  ·  Poland (1)  ·  Portugal (1)  ·  United Kingdom (1)

Top investigators

Najla El Jurdi, M.D. (2)  ·  James Lowder, MD (1)  ·  Martin McCarter (1)  ·  Mohammad Azab, MD (1)  ·  Pau Montesinos (1)  ·  Sanjay Mohan, MD (1)

Results publications

PMID 30926081, PMID 32285126, PMID 42235013